New Test to Detect T-Cell Immune Response to SARS-CoV-2 Using AI-Powered Platform Delivers Results in Real-Time

By LabMedica International staff writers
Posted on 27 Oct 2021

Image: Hyris Test quickly detects T-Cell response to SARS-CoV-2 (Photo courtesy of Hyris Ltd.)

A new test to detect T-cell immune response to SARS-CoV-2 leverages the power of an AI-powered platform that enables genetic testing in any setting, at any time, with results available in real-time.

Hyris Ltd. (London, UK) has developed the rapid T-Cell test to track patients' immunity levels to SARS-CoV-2 for global clinical and research use after having inked an exclusive licensing agreement with the Duke-NUS Medical School (Singapore). This new solution leverages the power of the renowned HYRIS bCUBE and the whole Hyris System. This disruptive platform enables genetic testing in any setting, at any time, with results available in real-time through its AI-powered platform.

The Hyris System, Hyris' proprietary genetic testing platform, is an ideal Point of Care solution in the fight against COVID-19. Thanks to the power of the extremely portable proprietary hardware HYRIS bCUBE, the Hyris System works anywhere and at any time, successfully detecting the presence of coronavirus on surfaces and environments (the SARS-CoV-2 Environmental test) and COVID-19 infection in individuals (SARS-CoV-2 Human test), including all the main variants of concern that have emerged since July 2020.

The T-Cell clinical test kit developed through an exclusive licensing agreement between Hyris and Duke-NUS Medical School allows rapid and large-scale expansion of studies to track T-cell activity across the world while not requiring specialized or expensive equipment. The simple and rapid method to measure T-cell immune response to the SARS-CoV-2 virus helps to define the correlates of protection from T Cells and antibodies for the development of COVID-19 vaccines. Such a test is a prime example of how scientific innovation is the key to the fight against the SARS-CoV-2 virus in order to boost population immunity.

"Alongside with limiting the spread of SARS-CoV-2 new variants and potential hotspots, getting high immunity rates among populations is number one priority for policymakers and health institutions," said Stefano Lo Priore, Founder and CEO at Hyris. "Hyris integrated its solutions with a simple yet effective test, to measure a patient T-cell immune response to the SARS-CoV-2 virus, which causes COVID-19."

Related Links:
Hyris Ltd.
Duke-NUS Medical School